The Week in Review: Shanghai Pharma Schedules Hong Kong IPO

Shanghai Pharma scheduled its upcoming $1.2 billion Hong Kong IPO for April; Dahuanong Animal Health Products raised $228 million in a ChiNext IPO; Simcere Pharma filed to begin a Phase I trial of a novel cancer mAb; Bristol-Myers Squibb announced WuXi PharmaTech will construct a dedicated facility for work on BMS drugs; Fenwal and Golden Meditech Holdings arrived at definitive terms for their medical device JV; the NDRC once again mandated price decreases for drugs, averaging 21% for 162 medicines; and WuXi PharmaTech , while announcing a solid 24% growth in revenues in 2010, predicted a further 20% increase for 2011. More details…. Stock Symbol: (SHA: 601607) (SHE: 300186) (NYSE: SCR) (NYSE: BMY) (NYSE: WX) (HK: 801; TW: 910801) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});